Scarica l'app Stockscreener
134.50
1.34%
1.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$132.72
Aprire:
$133.47
Volume 24 ore:
1.54M
Relative Volume:
0.79
Capitalizzazione di mercato:
$20.43B
Reddito:
$4.34B
Utile/perdita netta:
$850.00M
Rapporto P/E:
24.62
EPS:
5.4635
Flusso di cassa netto:
$921.00M
1 W Prestazione:
+11.22%
1M Prestazione:
+11.30%
6M Prestazione:
+40.90%
1 anno Prestazione:
+88.90%
Intervallo 1D:
$130.57
$135.58
Intervallo di 1 settimana:
$120.60
$135.58
Portata 52W:
$69.83
$155.53
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
134.50 | 20.16B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
526.60 | 191.76B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.75 | 137.14B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
589.25 | 45.27B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
121.87 | 33.42B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
327.77 | 31.32B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR Newswire
Robeco Institutional Asset Management B.V. Trims Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN), Labcorp (LH) expand precision oncology NGS collaboration - MSN
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Illumina Inc. stock (US4523271090): Why does its genomics dominance matter more now for U.S. investo - AD HOC NEWS
Illumina’s Pediatric Genomics Push Tests Long Term Growth Narrative - Yahoo Finance
How Investors Are Reacting To Illumina (ILMN) Board Turnover And Expanded Labcorp Precision Oncology Partnership - simplywall.st
Illumina partners with D3b on pediatric genomic data initiative - Investing.com
Illumina Partners with D3b to Advance Pediatric Cancer Research - Intellectia AI
100,000 child genomes power rare disease and cancer research - Stock Titan
Third View Private Wealth LLC Buys Shares of Illumina, Inc. - National Today
Administrator Loeffler Applauds SBIR-STTR Reauthorization - GlobeNewswire Inc.
Hardman Johnston Trims Illumina Stake - National Today
Illumina, Inc. $ILMN Shares Sold by Hardman Johnston Global Advisors LLC - MarketBeat
Illumina, Inc. $ILMN Holdings Decreased by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Baillie Gifford & Co. Reduces Position in Illumina, Inc. $ILMN - MarketBeat
Bioinformatics Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Illumina (ILMN), Labcorp (LH) Expand Precision Oncology NGS Collaboration - Insider Monkey
Epigenetics Market to Grow from US$ 2.06 Billion in 2024 to US$ - openPR.com
Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS
Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance
Is Illumina Stock Undervalued at $121? - TIKR.com
Illumina Inc stock (US4523271090): Is its genomics dominance strong enough to unlock new upside? - AD HOC NEWS
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Illumina Stock: Competitive Threats Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina Inc (ILMN) Stock Down 3.4% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Informatics advances reveal the TruPath™ Genome towards comprehensive genomic insights - Illumina
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 - marketscreener.com
Illumina will post Q1 results April 30, then hold a webcast - Stock Titan
[ARS] ILLUMINA, INC. SEC Filing - Stock Titan
Illumina Inc. stock rises Wednesday, still underperforms market - MarketWatch
(ILMN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Illumina, Inc. (ILMN) Stock Forecasts - Yahoo Finance
New Zealand gains genomic testing independence - Illumina
Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc - MarketBeat
The Evolving Landscape of Proteomics: HUPO World Congress Interview with Professor Stuart Cordwell - Illumina
Illumina rejigs board of directors - Medical Buyer
Cathie Wood's Called It Years Ago – Illumina Is the Must-Own Personalized Biotech Stock - Money Morning
Illumina, Inc. (ILMN) stock price, news, quote and history - Yahoo Finance Singapore
Illumina Inc (ILU.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina, Inc. (ILMN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina Stock Hits Day Low of $116.75 Amid Price Pressure - Markets Mojo
Cancer Biopsy Market Set to Boom Rapidly, Witnessing Strong - openPR.com
Illumina adds King to board as three directors retire By Investing.com - Investing.com Canada
Liquid Biopsy Products Market Is Going to Boom | Illumina • Biocept • Natera • Roche - openPR.com
Cardiogenetic testing at scale: the TruGenome Cardiovascular Disease Test and CardioSeq Clinical Trial - Illumina
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):